Müller-Tidow, C
Tschanter, P
Röllig, C
Thiede, C
Koschmieder, A
Stelljes, M
Koschmieder, S
Dugas, M
Gerss, J
Butterfaß-Bahloul, T
Wagner, R
Eveslage, M
Thiem, U
Krause, S W
Kaiser, U
Kunzmann, V
Steffen, B
Noppeney, R
Herr, W
Baldus, C D
Schmitz, N
Götze, K
Reichle, A
Kaufmann, M
Neubauer, A
Schäfer-Eckart, K
Hänel, M
Peceny, R
Frickhofen, N
Kiehl, M
Giagounidis, A
Görner, M
Repp, R
Link, H
Kiani, A
Naumann, R
Brümmendorf, T H
Serve, H
Ehninger, G
Berdel, W E
Krug, U
,
Article History
Received: 19 May 2015
Revised: 5 October 2015
Accepted: 8 October 2015
First Online: 2 November 2015
Competing interests
: CMT, PT, KG and UK received payment for lectures from Celgene Inc. CMT received research funding from Celgene Inc. and Amgen Inc. UK and CMT received travel expenses from Celgene Inc. and Amgen Inc. Azacitidine is a product of Celgene Inc. There are no further patents, products in development or marketed products to declare. The remaining authors declare no conflict of interest.